

1 **Protocol for the systematic review of the *Pneumocystis jirovecii*-associated pneumonia in**
2 **non-HIV immunocompromised patients**

3 Mauricio Ernesto Orozco-Ugarriza^{1,4¶}, Yuranis E. Rodger-Cervantes^{3¶}, Yenifer Olivo-
4 Martínez^{1,2¶}

5 ¹*Grupo de investigación en Microbiología y Ambiente (GIMA). Universidad de San*
6 *Buenaventura, Cartagena, Colombia.*

7 ²*Biochemistry and Diseases Research Group, Facultad de Medicina, Universidad de*
8 *Cartagena, Cartagena, Colombia.*

9 ³*Graduated from the Bacteriology and Clinical Laboratory Program, Faculty of Health*
10 *Sciences. Universidad de San Buenaventura Cartagena, Colombia.*

11 ⁴*Grupo de investigación traslacional en Biomedicina y Biotecnología (GITB&B). Corporación*
12 *para el desarrollo de la Investigación en Biomedicina & Biotecnología, Cartagena, Colombia.*

13

14 Corresponding Author:

15 *Mauricio E. Orozco-Ugarriza, Grupo de investigación en Microbiología y Ambiente (GIMA).

16 Universidad de San Buenaventura, Cartagena, Colombia. E-mail:

17 morozcou@usbcartagena.edu.co, mauricioorozcou@gmail.com.

18 ¶These authors contributed equally to this work.

19 **Abstract**

20 **Introduction**

21 *Pneumocystis jirovecii* pneumonia (PJP) is a well-known and frequent opportunistic infection in
22 HIV patients. However, there has been an increase in the number of reports of PJP in other
23 immunosuppressed patients with autoimmune inflammatory disorders or because of
24 chemotherapy and high doses of steroids, especially when used in combination as part of
25 immunosuppressive therapy.

26 **Objective**

27 Despite the increasing importance of PJP in non-HIV patients, there is a lack of comprehensive
28 and updated information on the epidemiology, pathogenesis, diagnosis, microbiology,
29 treatments, and prophylaxis of this infection in this population. Therefore, the objective of this
30 systematic review is to synthesize information on these aspects, from a perspective of evidence-
31 based medicine.

32 **Methods**

33 The protocol is prepared following the preferred reporting items for systematic reviews and
34 meta-analyses (PRISMA-P) guidelines. We will perform a systematic review from 2010 to 2022
35 in PubMed, Google Scholar, ScienceDirect, and Web of Science. In addition, manual searches
36 will be carried out through related articles, and references to included articles. The main
37 findings and clinical outcomes were extracted from all the eligible studies with a standardized
38 instrument. Two authors will independently screen titles and abstracts, review full texts, and
39 collect data. Disagreements will be resolved by discussion, and a third reviewer will decide if
40 there is no consensus. We will synthesize the results using a narrative or a meta-analytic
41 approach, depending on the heterogeneity of the studies.

42

43

44 **Expected results**

45 It is expected that this systematic review will provide a comprehensive and up-to-date overview
46 of the state-of-the-art of PJP in non-HIV patients. Furthermore, the study will highlight possible
47 gaps in knowledge that should be addressed through new research.

48 **Conclusions**

49 Here, we present the protocol for a systematic review which will consider all existing evidence
50 from peer-reviewed publication sources relevant to the primary and secondary outcomes related
51 to diagnosing and managing PJP in non-HIV patients.

52 **Systematic review registry**

53 This study was registered at the International Prospective Registry for Systematic Reviews
54 (PROSPERO registration number: [CRD42023429112](#))

55 **Keywords:** *Pneumocystis jirovecii* pneumonia (PJP), *Pneumocystis jirovecii*, Non-HIV,
56 immunocompromised host.

57 **Introduction**

58 *Pneumocystis jirovecii* pneumonia (PJP) is a fungal infection that mainly affects patients
59 with immune system disorders. It is a severe and potentially fatal disease, especially in
60 immunocompromised patients. One of the most common causes of immunosuppression is
61 human immunodeficiency virus (HIV) infection, which is strongly associated with PJP [1].
62 However, in recent years, the incidence of PJP has decreased in HIV patients is around 10–20%
63 [2], due to antiretroviral therapy and routine prophylaxis with trimethoprim-sulfamethoxazole
64 (TMP-SMX) [3].

65 In contrast, the prevalence of PJP has risen steadily and has emerged as a major cause of
66 morbidity and mortality among patients with non-HIV immunosuppression [4]. These patients
67 have different causes of immune system alterations that can increase the risk of developing PJP,
68 such as hematological or solid malignancies [5], organ transplantation [2], inflammatory or
69 autoimmune diseases [6], as well as immunosuppressive treatments [6,7].

70 The clinical presentation of PJP may differ between patients with and without HIV infection
71 [8], which may influence early detection and initiation of appropriate treatment [9]. Studies
72 have shown that PJP in non-HIV patients experiences a more progressive clinical course, a poor
73 prognosis, and a higher mortality rate (ranging from 30% to 60%) than in HIV patients [4,10].
74 This is due to several factors, such as delay in diagnosis, lack of prevention, advanced age,
75 comorbidities, and immunosuppression. Therefore, early diagnosis is key to allowing evaluation
76 of the patient's clinical status and choice of the best anti-PJP therapy, which may include TMP-
77 SMX or other options, as appropriate, to improve prognosis [11].

78 The prevention and management of PJP in non-HIV patients remain a challenge in the
79 medical field. There is currently no standard guideline for the prophylaxis of this infection in
80 this group, and the decision to start prophylaxis depends on the individual risk-benefit
81 assessment for each patient [4]. It is essential to improve our understanding of the risk factors
82 and to carry out a personalized evaluation of the patients [12]. An early diagnosis and

83 appropriate therapy can make a difference in the prognosis of the disease [13]. Several studies
84 have identified risk factors for PJP in non-HIV patients, such as the concomitant use of
85 corticosteroids and immunosuppressants, lymphopenia, and a CD4+ T cell count below 200
86 cells/ μ L [14,15]. However, it is crucial to highlight that the CD4+ T cell count, used as an
87 indicator of immune function and the risk of developing opportunistic infections in HIV
88 patients, is not a reliable criterion for the prophylaxis of PJP in non-HIV patients [4,10]. This is
89 because it can vary depending on the cause of immunosuppression and not reflect the actual
90 immune status of the patient [16].

91 The diagnosis of PJP is based on clinical presentation, radiological findings, and
92 confirmation by observing the organisms in stained respiratory samples [17]. However, *P.*
93 *jirovecii* is extremely difficult to cultivate *in vitro*, which poses significant challenges in the
94 diagnosis, treatment, and prevention of the disease. Despite these difficulties, there are currently
95 more efficient laboratory tools for the diagnosis of *P. jirovecii*, such as polymerase chain
96 reaction (PCR) and immunofluorescence assays, which have improved our ability to identify
97 cases of PJP [13,18]. However, due to the difficulty of cultivating this organism *in vitro*
98 conditions, our understanding of numerous aspects of pneumocystosis, including the host
99 immune responses to the organism and the immunopathology of this infection, remains limited
100 [19]. Given this limitation, the current information on the basic aspects of PJP has been obtained
101 mainly from some limited clinical studies and experiments in rodent models [20]. These sources
102 of information may not fully reflect the reality of PJP in human patients, so more research is
103 required to improve the diagnosis, prevention, and treatment of this infection.

104 Considering the serious consequences of PJP in immunocompromised patients due to
105 causes other than HIV, in this article, we present a protocol to perform a systematic review. This
106 systematic review aims to synthesize information on the epidemiology, pathogenesis, diagnosis,
107 microbiology, treatments, and prophylaxis of PJP in these patients, from an evidence-based
108 medicine perspective. This systematic review is expected to provide clarity on the current state

109 of knowledge and identify research gaps, ultimately contributing to better management of PJP
110 in non-HIV patients.

111 **Methods**

112 **Design and registration**

113 This systematic review protocol has been conducted following the recommendations of the
114 Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA-P) guidelines
115 [21]. This review protocol was registered in the Prospective Register of Systematic Reviews
116 platform (PROSPERO) [22], (registration number CRD42023429112), and can be accessed at
117 https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023429112. See (S1
118 Checklist) for the completed PRISMA-P checklist. We will only make changes to the study
119 protocol if necessary and we will report them in the PROSPERO record.

120 **Search strategy**

121 The search strategy will be conducted comprehensively across electronic databases,
122 including PubMed, Google Scholar, ScienceDirect, and Web of Science. Controlled terms (also
123 known as Medical Subject Headings or MeSH terms) and relevant keywords will be used to
124 identify relevant studies related to *Pneumocystis jirovecii*-associated pneumonia in non-HIV
125 immunosuppression, such as "*Pneumocystis jirovecii*", "*Pneumocystis carinii*",
126 "pneumocystosis", "pneumonia", "non-HIV", "without HIV diagnosis",
127 "immunocompromised", "immunosuppression", "cancer", "transplantation", "autoimmune", and
128 "inflammatory", "incidence", "clinical characteristics", "risk factors" and "therapeutic
129 management".

130 We will use Boolean operators (such as AND, OR, NOT) and filters to refine the search
131 results. We will also perform manual searches through related articles, and references of
132 included articles, to identify additional relevant studies.

133 The pilot search will be adapted to each database, avoiding any inconsistencies that may
134 affect data extraction and ensuring that the final search strategy is correctly adapted. The details
135 of the search strategy, including the terms used and filters applied, will be recorded to ensure
136 transparency and reproducibility of the systematic review. A sample search strategy for PubMed
137 is available as supporting information (S2 File). Full search strategies will be provided in the
138 complete review.

139 **Eligibility criteria**

140 We will include studies that meet the following criteria:

141 Population: Patients with non-HIV immunosuppression, defined as having any condition or
142 treatment that alters the immune system function, such as hematological or solid malignancies,
143 organ transplantation, inflammatory or autoimmune diseases, or immunosuppressive drugs.

144 Intervention: Any intervention for the diagnostic, therapeutic, or prophylactic measure for
145 PJP, such as laboratory tests; radiological exams; antifungal drugs; and preventive measures.
146 The type, duration, frequency, dosage, route, or any other relevant characteristic of the measure
147 will be specified, respectively.

148 Exposure: Any risk factor, cause, agent, or situation associated with PJP, such as
149 immunosuppression, organ transplantation, autoimmune diseases, corticosteroid use, exposure
150 to the *P. jirovecii* fungus, or underlying medical conditions, immunosuppressive therapies,
151 environmental exposures, or genetic predisposition, will be specified for type, duration,
152 frequency, dosage, route, or any other relevant characteristic.

153 Comparator: We will have two types of comparators including 1) HIV patients with PJP,
154 the most well-known and common group affected by this infection. 2) Any comparator for the
155 intervention, such as different tests, drugs, doses, durations, or strategies.

156 Outcome: Any outcome related to PJP, such as incidence, prevalence, mortality, morbidity,
157 and adverse effects.

158 Study design: We will include original articles with an observational and interventional
159 design, as well as systematic reviews and meta-analyses, that report data on PJP in non-HIV
160 patients and outcomes of interest (incidence, clinical characteristics, risk factors, and therapeutic
161 management). We will exclude case reports, case series, letters, editorials, and reviews that do
162 not provide original data.

163 Publication date: The search will be limited to studies published between 2010 and 2022,
164 aiming to capture the most up-to-date evidence on PJP in non-HIV patients.

165 Language: We will include studies published in English or Spanish, as these are the
166 languages that the reviewers can read and understand. However, efforts will be made to identify
167 and access relevant studies published in other languages if possible.

168 **Literature screening and study selection**

169 We plan to make use of a flow diagram to summarize the article screening process and
170 detail the reasons for the exclusion of studies screened as full text. This will follow the PRISMA
171 guidelines for reporting systematic reviews [23]. The report will feature a PRISMA-compliant
172 flow chart illustrating the process of study screening and selection, as depicted in the S3 file.

173 All studies retrieved by the searches will be combined using the Mendeley software
174 desktop, and duplicates will be removed. All articles returned by the search procedure will be
175 divided between the authors (MEOU and YRC), who will independently conduct a 3-step
176 screening (titles, abstracts, and full texts) and decide on their inclusion or exclusion. Any
177 disagreement between the reviewers will be resolved by discussion, and a third reviewer (YOM)
178 will decide if there is no consensus.

179 **Data extraction**

180 Data will be collected independently by three individual reviewers from each eligible
181 publication, and the extracted data items, using a standardized data extraction form (See S4
182 File). The data will be exported to Excel (the spreadsheet software). After completing the

183 selection and screening of the studies, data extraction will be conducted in four stages: 1)
184 development of a data extraction form, 2) peer-review of the data extraction form, 3) pilot test
185 of the data extraction form, and 4) final data extraction.

186 **Data items**

187 The following data items will be extracted from the included studies:

188 **Identification of the study:** This will include the name of the journal, article DOI, article
189 title, authors, publication year, short citation, and country.

190 **Methods:** This will include the study objectives, study design, inclusion and exclusion
191 criteria, intervention (type, dose, duration, frequency, mode of administration), intervention
192 characteristics, comparator characteristics (if applicable), diagnostic methods, participant
193 demographics (mean age, sex, number of participants), and description of effect and effect size
194 (if applicable), and results (summary statistics, effect estimates, confidence intervals, p-values,
195 subgroup analyses, sensitivity analyses, risk of bias, quality of evidence).

196 **Main findings:** This will include diagnosis, patient characteristics, and other relevant
197 clinical outcome measures (definition, assessment, time point). One-sentence conclusion of the
198 study.

199 **Methodological quality assessment**

200 For the systematic review, the method of assessing the risk of bias or study quality will
201 involve the following steps:

202 **Independent assessment:** Two reviewers (MEOU and YRC), will independently evaluate the
203 methodological quality of the included studies or literature.

204 **Disagreement resolution:** Any disagreements between reviewers' assessments will be
205 resolved through discussion and consensus, in cases where consensus cannot be reached, a third
206 reviewer (YOM) will be involved to reach a final agreement.

207 Study selection and data extraction: Two reviewers will independently assess the search
208 results and select high-quality literature for inclusion in the review. Multiple reviewers will be
209 involved in the data extraction process, to minimize the risk of errors.

210 Blinding: The study selection, data extraction, and risk of bias assessment will be performed
211 without blinding the assessors to the study authors or the journal of publication.

212 These measures are implemented to ensure the rigor and reliability of the review process.
213 By involving multiple independent reviewers and resolving disagreements through discussion
214 and consensus, the risk of bias in the included studies will be assessed transparently and
215 comprehensively.

216 **Strategy for data synthesis**

217 We plan to synthesize the data using a systematic narrative synthesis approach, to provide a
218 comprehensive view of the topic by presenting a coherent narrative that integrates the primary
219 findings from the included studies. This synthesis will involve summarizing data extracted from
220 the included studies, with a specific focus on clinical characteristics, risk factors, therapeutic
221 treatments, and other interventions, as well as the methodological quality of the studies and any
222 identified limitations. When appropriate, we will categorize these findings into relevant groups
223 to facilitate a clearer presentation of the synthesized data. Additionally, we will employ
224 descriptive statistics to analyze the results, where feasible. These measures will contribute to a
225 comprehensive and coherent synthesis of the data, enabling a deeper understanding of the topic,
226 its clinical implications, and the quality of the underlying evidence.

227 **Ethics**

228 This is a systematic review that will use published data and does not require ethical
229 approval.

230

231

232 **Status of the study and dissemination plan**

233 We are currently selecting the records based on the eligibility criteria applied to the titles
234 and abstracts. This systematic review is ongoing, and we expect to complete the project, publish
235 the results in a peer-reviewed journal, and report them in 12 months. We will follow the updated
236 PRISMA guideline to report the final paper and register it on the PROSPERO website. All the
237 data will be accessible as supplementary information when the review is completed. Moreover,
238 we will also present the main findings at academic conferences and relevant professional
239 meetings.

240 **Discussion**

241 In this systematic review protocol, a detailed plan of all steps of the review has been
242 described, including protocol development, search strategy, study selection, data extraction,
243 quality assessment, and synthesis of data, to ensure the production of unbiased evidence on PJP
244 in patients with non-HIV immunosuppression, its clinical characteristics, risk factors,
245 treatments, and available interventions. The knowledge obtained from this review can contribute
246 to better prevention, diagnosis, and management of this disease, which has increased its
247 incidence and mortality in recent years. Furthermore, it can identify existing knowledge gaps
248 and suggest possible future lines of research.

249 **Conclusion**

250 The PJP is a serious and potentially fatal opportunistic infection that affects
251 immunocompromised patients, especially those who are not infected by HIV. The diagnosis and
252 management of PJP in non-HIV patients pose significant challenges, as there are no clear
253 guidelines or consensus on the optimal strategies. Therefore, it is important to conduct a
254 systematic review that synthesizes the available evidence on the clinical characteristics, risk
255 factors, treatments, and interventions for PJP in non-HIV patients. In this protocol, we describe
256 the methods and criteria that we will use to perform a comprehensive and up-to-date search,
257 selection, extraction, quality assessment, and synthesis of data from peer-reviewed publications

258 relevant to the primary and secondary outcomes of interest. We expect that this systematic
259 review will provide a state-of-the-art overview of the current knowledge and practice of PJP in
260 non-HIV patients, as well as identify the existing knowledge gaps and suggest possible future
261 lines of research.

262 **Supporting information**

263 S1 Checklist. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols

264 (PRISMA-P checklist).

265 (PDF)

266 S2 File. Sample search strategy for PubMed.

267 (DOCX)

268 S3 File. PRISMA 2009 flow diagram.

269 (DOCX)

270 S4 File. Data extraction form for systematic review.

271 (DOCX)

272 S5 File. PROSPERO registration.

273 (PDF)

274 **Acknowledgments**

275 The authors would like to thank all members of the group for their support and help.

276

277

278

279

280

281

282

283 **Author contributions**

284 Conceptualization: Mauricio Ernesto Orozco-Ugarriza, Yuranis E. Rodger-Cervantes, Yenifer
285 Olivo-Martínez

286 Data curation: Mauricio Ernesto Orozco-Ugarriza, Yuranis E. Rodger-Cervantes, Yenifer Olivo-
287 Martínez

288 Investigation: Yuranis E. Rodger-Cervantes

289 Methodology: Mauricio Ernesto Orozco-Ugarriza, Yuranis E. Rodger-Cervantes,

290 Supervision: Mauricio Ernesto Orozco-Ugarriza

291 Validation: Mauricio Ernesto Orozco-Ugarriza, Yuranis E. Rodger-Cervantes, Yenifer Olivo-
292 Martínez

293 Visualization: Mauricio Ernesto Orozco-Ugarriza, Yuranis E. Rodger-Cervantes, Yenifer Olivo-
294 Martínez

295 Writing – original draft: Mauricio Ernesto Orozco-Ugarriza, Yuranis E. Rodger-Cervantes,
296 Yenifer Olivo-Martínez

297 Writing – review and editing: Mauricio Ernesto Orozco-Ugarriza, Yuranis E. Rodger-Cervantes,
298 Yenifer Olivo-Martínez

299 All authors read and approved the final manuscript.

300 **Funding**

301 No funding was received for the development of this protocol.

302 **Availability of data and materials**

303 All data from this study will be made available in the online databases upon study completion.

304 **Ethics approval and consent to participate.**

305 This study has no ethics approval needed.

306 **Consent for publication**

307 No need for consent for research and publication.

308 **Competing interests**

309 The authors declare that they have no competing interests.

310 **References**

- 311 1. Hof H. *Pneumocystis jirovecii*: A peculiar fungus posing particular problems for therapy
312 and prophylaxis. *Mycoses*. 2012;55. doi:10.1111/j.1439-0507.2011.02159.x
- 313 2. Duan J, Gao J, Liu Q, Sun M, Liu Y, Tan Y, et al. Characteristics and Prognostic Factors
314 of Non-HIV Immunocompromised Patients With *Pneumocystis* Pneumonia Diagnosed
315 by Metagenomics Next-Generation Sequencing. *Front Med (Lausanne)*. 2022;9.
316 doi:10.3389/fmed.2022.812698
- 317 3. Castro JG, Morrison-Bryant M. Management of *Pneumocystis jirovecii* pneumonia in
318 HIV infected patients: Current options, challenges and future directions. *HIV/AIDS -*
319 *Research and Palliative Care*. 2010;2. doi:10.2147/hiv.s7720
- 320 4. Huang L, Xu S, Huang Z, Chen Y, Xu N, Xie B. Risk factors associated with
321 *Pneumocystis jirovecii* pneumonia in non-HIV immunocompromised patients and co-
322 pathogens analysis by metagenomic next-generation sequencing. *BMC Pulm Med*.
323 2023;23. doi:10.1186/s12890-022-02300-8
- 324 5. Kofteridis DP, Valachis A, Velegraki M, Antoniou M, Christofaki M, Vrentzos GE, et
325 al. Predisposing factors, clinical characteristics and outcome of *Pneumocystis jirovecii*
326 pneumonia in HIV-negative patients. *Journal of Infection and Chemotherapy*. 2014;20.
327 doi:10.1016/j.jiac.2014.03.003
- 328 6. Chan SCW, Chung HY, Lau CS, Li PH. Epidemiology, mortality and effectiveness of
329 prophylaxis for *Pneumocystis jirovecii* pneumonia among rheumatic patients: a territory-
330 wide study. *Ann Clin Microbiol Antimicrob*. 2021;20. doi:10.1186/s12941-021-00483-2
- 331 7. Xia S, Gong H, Wang YK, Liu L, Zhao YC, Guo L, et al. *Pneumocystis jirovecii*
332 pneumonia associated with immune checkpoint inhibitors: A systematic literature review
333 of published case reports and disproportionality analysis based on the FAERS database.
334 *Front Pharmacol*. 2023;14. doi:10.3389/fphar.2023.1129730
- 335 8. Nasr M, Mohammad A, Hor M, Baradeiya AM, Qasim H. Exploring the Differences in
336 *Pneumocystis* Pneumonia Infection Between HIV and Non-HIV Patients. *Cureus*. 2022.
337 doi:10.7759/cureus.27727
- 338 9. Kim TO, Lee JK, Kwon YS, Kim Y Il, Lim SC, Kim MS, et al. Clinical characteristics
339 and prognosis of patients with *Pneumocystis jirovecii* pneumonia without a
340 compromised illness. *PLoS One*. 2021;16. doi:10.1371/journal.pone.0246296

- 341 10. Merrill ME, Simonetti JA. Risk of and prophylaxis against PCP pneumonia among HIV-
342 uninfected individuals. *J Gen Intern Med.* 2018;33.
- 343 11. Assal M, Lambert J, Chow-Chine L, Bisbal M, Servan L, Gonzalez F, et al. Prognostic
344 impact of early adjunctive corticosteroid therapy in non-HIV oncology or haematology
345 patients with *Pneumocystis jirovecii* pneumonia: A propensity score analysis. *PLoS One.*
346 2021;16. doi:10.1371/journal.pone.0250611
- 347 12. Ghembaza A, Vautier M, Cacoub P, Pourcher V, Saadoun D. Risk Factors and
348 Prevention of *Pneumocystis jirovecii* Pneumonia in Patients With Autoimmune and
349 Inflammatory Diseases. *Chest.* 2020. doi:10.1016/j.chest.2020.05.558
- 350 13. Li MC, Lee NY, Lee CC, Lee HC, Chang CM, Ko WC. *Pneumocystis jirovecii*
351 pneumonia in immunocompromised patients: Delayed diagnosis and poor outcomes in
352 non-HIV-infected individuals. *Journal of Microbiology, Immunology and Infection.*
353 2014;47. doi:10.1016/j.jmii.2012.08.024
- 354 14. Watanabe Y, Hayashi K, Terai S. A Rare Case of Ulcerative Colitis with Severe
355 *Pneumocystis jirovecii* Pneumonia and Cytomegalovirus Colitis: A Case Report and
356 Literature Review. *Internal Medicine.* 2022. doi:10.2169/internalmedicine.7953-21
- 357 15. Viceconte G, Buonomo AR, D'Agostino A, Foggia M, Di Fusco A, Pinchera B, et al.
358 Risk Factors for *Pneumocystis jirovecii* Pneumonia in Non-HIV Patients Hospitalized
359 for COVID-19: A Case-Control Study. *Journal of Fungi.* 2023;9.
360 doi:10.3390/jof9080838
- 361 16. Atkinson A, Miro JM, Mocroft A, Reiss P, Kirk O, Morlat P, et al. No need for
362 secondary *Pneumocystis jirovecii* pneumonia prophylaxis in adult people living with
363 HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than
364 100 cells/ μ L. *J Int AIDS Soc.* 2021;24. doi:10.1002/jia2.25726
- 365 17. Dunbar A, Schauwvlieghe A, Algae S, van Hellemond JJ, Reynders M, Vandecasteele S,
366 et al. Epidemiology of *Pneumocystis jirovecii* Pneumonia and (Non-)use of Prophylaxis.
367 *Front Cell Infect Microbiol.* 2020;10. doi:10.3389/fcimb.2020.00224
- 368 18. Grønseth S, Rogne T, Hannula R, Åsvold BO, Afset JE, Damås JK. Epidemiological and
369 clinical characteristics of immunocompromised patients infected with *Pneumocystis*
370 *jirovecii* in a twelve-year retrospective study from Norway. *BMC Infect Dis.* 2021;21.
371 doi:10.1186/s12879-021-06144-1

- 372 19. Charpentier E, Ménard S, Marques C, Berry A, Iriart X. Immune response in
373 pneumocystis infections according to the host immune system status. *Journal of Fungi*.
374 2021. doi:10.3390/jof7080625
- 375 20. Elsegeiny W, Zheng M, Eddens T, Gallo RL, Dai G, Trevejo-Nunez G, et al. Murine
376 models of Pneumocystis infection recapitulate human primary immune disorders. *JCI*
377 *Insight*. 2018;3. doi:10.1172/jci.insight.91894
- 378 21. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred
379 reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015
380 statement. *Syst Rev*. 2015;4: 1. doi:10.1186/2046-4053-4-1
- 381 22. Schiavo JH. PROSPERO: An International Register of Systematic Review Protocols.
382 *Medical Reference Services Quarterly*. 2019. doi:10.1080/02763869.2019.1588072
- 383 23. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
384 PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *The*
385 *BMJ*. 2021. doi:10.1136/bmj.n71
- 386